Contact Us
Drug Search Results
More Filters [+]

Phenoxodiol

Alternative Names: phenoxodiol, idronoxil, Veyonda
Latest Update: 2023-10-03
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Akt Inhibitor,CAAP Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: Orphan Drug - Sarcoma *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: MARSHALL EDWARDS PTY
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Phenoxodiol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer

Phase 2: Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Prostate Cancer|Adenocarcinoma

Phase 1: Prostate Cancer|Breast Cancer|Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
LuPin

P1

Completed

Prostate Cancer

2020-02-06

NOX66 version 1

P1

Terminated

Prostate Cancer

2019-09-17

(OVATURE)

P3

Completed

Peritoneal Cancer|Ovarian Cancer

2011-06-16

YALE-HIC-27640

P1

Terminated

Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer

2009-08-01

Recent News Events

Date

Type

Title

10/03/2023

PubMed

 Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-Seq and Bulk RNA-Seq Analysis in GC.

09/26/2023

PubMed

 Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617.

09/18/2023

PubMed

 Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection.

03/29/2022

News Article

 FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

03/08/2022

News Article

 Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

12/01/2021

News Article

 Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

11/09/2021

News Article

 Noxopharm Announces DARRT-2 Clinical Trial in U.S.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions